


PHARMACEUTICAL 2023

AXIM BIOTECHNOLOGIES INC. Rank 384 of 446





PHARMACEUTICAL 2023

AXIM BIOTECHNOLOGIES INC. Rank 384 of 446

The relative strengths and weaknesses of AXIM BIOTECHNOLOGIES INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AXIM BIOTECHNOLOGIES INC. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 157% points. The greatest weakness of AXIM BIOTECHNOLOGIES INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 167% points.

The company's Economic Capital Ratio, given in the ranking table, is -172%, being 215% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	104
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,392
Liabilities, Non-Current	5,645
Other Assets	4,014
Other Compr. Net Income	0
Other Expenses	426
Other Liabilities	0
Other Net Income	1,590
Other Revenues	8.9
Property and Equipment	94
Research and Development	154
Selling, General and Administrative Expense	4,082

Output Variable	Value in 1000 USD
Assets	4,212
Liabilities	9,037
Expenses	4,662
Revenues	8.9
Stockholders Equity	-4,825
Net Income	-3,063
Comprehensive Net Income	-3,063
Economic Capital Ratio	-172%

